Celldex Therapeutics, Inc. (NASDAQ:CLDX)
| CAPS Rating |
|
|---|
CLDX
VS S&P 500 (SPY)
CLDX News and Commentary
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2 – SeekingAlpha
- Finding a Pathway to Approval – The Motley Fool
- NetApp and American Capital Mortgage Investment Corporation Among Most Active Stocks in Pre-Market T – Minyanville
- Pre-Market Most Active for May 24, 2012 : BAC, PPL, EMC, NTAP, HPQ, MTGE, CLDX, TS, FB, MT, QQQ, VO – NASDAQ
- After Hours Most Active for May 23, 2012 : NTAP, HPQ, BAC, BLK, IFSIA, QQQ, F, CLDX, KMI, PFE, ERIC – NASDAQ
- An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABP – 247wallst
- NASDAQ Changes Up Biotech Index Members & Weightings – 247wallst
- Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CY – 247wallst
- Cancer Cures: ASCO Stocks to Give Your Portfolio a Boost – The Motley Fool
How do you think CLDX will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
215
Outperform
12
Underperform
All-Star Players
33
Outperform
4
Underperform
Wall Street
6
Outperform
0
Underperform
RSS Headlines
Fool UK
